NCT04637009 2024-08-02A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsAstex Pharmaceuticals, Inc.Phase 1 Terminated20 enrolled